COSENTYXHCP.COM

In the ERASURE study at week 12, 82% of patients in the COSENTYX 300-mg arm (n=245) achieved a PASI 75 response and 65% of patients achieved IGA 0 or 1 vs 4% and 2% in the placebo group (n=248), respectively. In the FIXTURE study at week 12, 76% of patients in the COSENTYX 300-mg arm (n=327) achieved a PASI 75 response and 62% achieved IGA 0 or 1 vs 5% and 3% in the placebo group (n=326), respectively. In the FUTURE 2 study, for patients with active psoriatic arthritis treated with COSENTYX 300 mg (n=100), 150 mg (n=100), or placebo (n=98), ACR20 response at week 24 was 54%, 51%, and 15%, respectively. In the ERASURE (N=738) and FIXTURE (N=1306) studies, among the subjects who chose to participate (39%) in assessments of patient-reported outcomes, improvements in signs and symptoms related to itching, pain, and scaling at week 12 compared with placebo were observed using the Psoriasis Symptom Diary©.ACR, American College of Rheumatology; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.

Reference: Cosentyx [prescribing information].
East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020.

MINIMIZE
In the ERASURE study at week 12, 82% of patients in the COSENTYX 300-mg arm (n=245) achieved a PASI 75 response and 65% of patients achieved IGA 0 or 1 vs 4% and 2% in the placebo group (n=248), respectively. In the FIXTURE study at week 12, 76% of patients in the COSENTYX 300-mg arm (n=327) achieved a PASI 75 response and 62% achieved IGA 0 or 1 vs 5% and 3% in the placebo group (n=326), respectively. In the FUTURE 2 study, for patients with active psoriatic arthritis treated with COSENTYX 300 mg (n=100), 150 mg (n=100), or placebo (n=98), ACR20 response at week 24 was 54%, 51%, and 15%, respectively. In the ERASURE (N=738) and FIXTURE (N=1306) studies, among the subjects who chose to participate (39%) in assessments of patient-reported outcomes, improvements in signs and symptoms related to itching, pain, and scaling at week 12 compared with placebo were observed using the Psoriasis Symptom Diary©.
ACR, American College of Rheumatology; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index.
Reference: Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020.